세계의 갑상선안증 치료제 시장 : 치료 유형별, 투여 경로별, 유형별, 진단별, 최종사용자별, 유통별 - 예측(2025-2030년)

The Thyroid Eye Disease Treatments Market was valued at USD 2.67 billion in 2024 and is projected to grow to USD 2.83 billion in 2025, with a CAGR of 5.94%, reaching USD 3.78 billion by 2030.

Thyroid eye disease (TED) presents both clinical complexities and evolving therapeutic opportunities that are reshaping the manner in which healthcare providers manage this challenging condition. Over recent years, remarkable progress has been made in understanding the underlying pathology and implementing diverse treatment strategies, from conservative medical interventions to surgical remedies. This executive summary delves into the multifaceted landscape of TED treatments, detailing the scientific advances and strategic insights that have redefined patient care. In this introductory section, the focus is on framing the critical aspects of the current treatment environment, highlighting how innovations in therapy and diagnostic methodologies are influencing clinical decisions and improving patient outcomes. As research deepens and new treatment modalities emerge, stakeholders are witnessing a transformation in clinical practice that demands robust analysis and strategic foresight. The evolution in therapeutic approaches underscores the necessity of an integrative perspective-one that not only considers the biological and clinical factors but also the market dynamics and regulatory drivers that shape treatment paradigms. This detailed exploration serves as a ground-breaking overview for decision-makers, paving the way for a deeper understanding and strategic discussion throughout the subsequent sections.

Transformative Shifts Redefining the Thyroid Eye Disease Treatment Landscape

In recent years, the landscape of thyroid eye disease treatment has undergone significant transformative shifts, driven by both scientific innovations and changing market dynamics. Advanced imaging technologies and enhanced diagnostic protocols have reshaped how clinicians diagnose and classify TED, enabling earlier intervention and more tailored treatment strategies. The emergence of targeted therapies, particularly in the realm of immunomodulatory and biologic treatments, reflects a broader shift toward personalized medicine. These advances are coupled with a growing emphasis on minimally invasive surgical procedures that complement traditional medical treatments. As clinical practices evolve, economic considerations and healthcare policies further influence treatment selections and investment in research and development. This transformation is not only altering the therapeutic mix but also broadening the scope of patient management, integrating multi-disciplinary collaborations between endocrinologists, ophthalmologists, and surgical experts. The comprehensive changes within this ecosystem highlight the critical role of technological integration, strategic partnerships, and regulatory adaptations. In this context, leaders in the field are urged to align their strategic vision with innovations that address unmet needs and improve both the efficacy and quality of care. This dynamic environment demands a proactive approach to adapt to rapid changes and to harness emerging opportunities in research and clinical practice.

Key Segmentation Insights Informing Targeted Strategies

A careful dissection of market segmentation reveals a detailed structure that is crucial for crafting targeted and effective strategies for TED treatments. When considering treatment types, the market distinctly differentiates between medical and surgical interventions. The medical treatment arm is meticulously analyzed through a spectrum of therapies that include corticosteroids, immunosuppressants, monoclonal antibodies, agents for thyroid hormone control, and tyrosine kinase inhibitors. Conversely, surgical treatment strategies are further explored through procedures such as eyelid surgery, orbital decompression surgery, and strabismus surgery. In tandem with treatment modality, the route of administration-a key determinant of both efficacy and patient compliance-has been scrutinized in terms of intravenous, oral, and topical applications. Additionally, segmenting the market by disease type, namely between Type I TED and Type II TED, offers further clarity in tailoring interventions. Diagnostic methodologies form another important segmentation layer that tracks the market through various tests including blood tests, imaging tests, orbital ultrasound, and radioactive iodine uptake tests. Analysis extends to the end-user dimension, where care settings span from hospitals and outpatient centers to specialty clinics, each presenting unique opportunities and challenges. Finally, distribution channels play a critical role, with market oversight including hospital pharmacy networks, online pharmacies, and traditional retail pharmacies. Each segmentation facet contributes to a compounding narrative that not only illuminates current trends but also directs future research, investment decisions, and clinical strategies.

Based on Treatment Type, market is studied across Medical Treatment and Surgical Treatment. The Medical Treatment is further studied across Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Thyroid Hormone Control, and Tyrosine Kinase Inhibitors. The Surgical Treatment is further studied across Eyelid Surgery, Orbital Decompression Surgery, and Strabismus Surgery.

Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.

Based on Type, market is studied across Type I TED and Type II TED.

Based on Diagnosis, market is studied across Blood Test, Imaging Test, Orbital Ultrasound, and Radioactive Iodine Uptake Test.

Based on End-User, market is studied across Hospitals, Outpatient Centers, and Specialty Clinics.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Key Regional Insights Shaping Global Market Dynamics

The TED treatment market is characterized by distinct regional variations, reflecting both local healthcare infrastructure and regional economic dynamics. In the Americas, robust healthcare spending, coupled with strong research and development initiatives, creates a fertile ground for innovation and rapid adoption of advanced therapeutic modalities. Meanwhile, Europe, Middle East & Africa experience a blend of mature healthcare markets and emerging opportunities, driven by a careful balance between tradition and innovation. European nations, in particular, continually enhance diagnostic technologies and treatment protocols, while markets in the Middle East and Africa adapt rapidly to dynamic demand patterns through strategic partnerships and policy reforms. The Asia-Pacific region stands out with its fast-growing healthcare infrastructure and increasing investment in research, making it a pivotal arena for both new market entrants and established players. These regional insights underscore the critical need for tailored strategies that address local demands while leveraging global best practices. Interregional differences in regulatory frameworks, reimbursement policies, and patient preferences remain at the core of strategic decision-making processes that drive market growth and innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Competitive Landscape and Innovation

The competitive arena of thyroid eye disease treatment is populated by a diverse group of key companies that drive innovation, invest in advanced research, and expand their market presence. Market leaders including Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, and Bausch & Lomb Incorporated are at the forefront of developing novel therapeutic interventions and enhancing patient care. In addition, companies such as Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, and Dr. Reddy's Laboratories Ltd. continue to push the boundaries of both medical and surgical treatment options. Prominent names such as Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, and H. Lundbeck A/S reaffirm the commitment to robust innovation pipelines and targeted clinical solutions. Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., and Johnson & Johnson Services Inc. bring to the table significant advancements and an acute understanding of market needs. The competitive landscape is further enriched by Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc., each contributing distinct approaches that range from breakthrough therapies to enhanced surgical techniques. This confluence of expertise reinforces the industry's multifaceted approach in addressing the clinical complexities of thyroid eye disease and sets the stage for future growth and competitive differentiation.

The report delves into recent significant developments in the Thyroid Eye Disease Treatments Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, Bausch & Lomb Incorporated, Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, H. Lundbeck A/S, Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc.. Actionable Recommendations for Navigating the Transformative Market

Industry leaders are encouraged to adopt a proactive and strategic approach in order to capitalize on the rapidly transforming landscape of thyroid eye disease treatments. Stakeholders should prioritize investment in innovative therapeutic research, particularly in the sphere of targeted biologics and minimally invasive surgical techniques. Given the nuanced segmentation across treatment types, routes of administration, disease types, and diagnostic protocols, it is essential to develop tailored strategies that address individual patient profiles and local market dynamics. Emphasis should be placed on integrating advanced diagnostic tools and data analytics into routine clinical practice, which not only improves precision but also facilitates early intervention. Furthermore, forging robust strategic alliances, both on a regional and cross-regional level, can help in pooling expertise and expediting the adoption of best practices. There is a clear imperative for optimizing distribution networks to ensure timely accessibility of therapies, alongside streamlining processes within hospital and online pharmacy channels. Overall, a deepened focus on understanding market segmentation, regional disparities, and the competitive landscape will provide industry leaders with the insights needed to mitigate risk and harness the substantial opportunities inherent in this evolving therapeutic domain.

Conclusion: Embracing a Future of Innovation and Personalized Care

In conclusion, the landscape of thyroid eye disease treatments is characterized by a dynamic interplay between innovation, strategic market segmentation, and evolving regional dynamics. As stakeholders navigate the complex therapeutic ecosystem, it is imperative to consider the diversity of treatment modalities, ranging from cutting-edge medical interventions to refined surgical techniques. The in-depth segmentation analysis - encompassing treatment type, route of administration, disease classification, diagnostic methodology, end-user setting, and distribution channels - has revealed not only the intricacies of current practices but also the directions for future innovation and strategic planning. Moreover, regional insights indicate that while the Americas and Europe, Middle East & Africa provide robust infrastructure and progressive policy environments, the Asia-Pacific market offers immense potential with its rapid expansion and increasing research investments. Coupled with the competitive drive of leading companies, the market is poised for transformative growth that prioritizes personalized care and data-driven decision making. This comprehensive review underscores the necessity for adaptability and strategic foresight among clinicians, manufacturers, and policy makers, all of whom play pivotal roles in shaping the future of TED treatment paradigms.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising global incidence and prevalence of thyroid disorders necessitates effective treatment options
    • 5.1.1.2. Increasing awareness about symptoms and treatments for thyroid eye disease among healthcare providers
  • 5.1.2. Restraints
    • 5.1.2.1. Concern associated with frequent product recalls of thyroid eye disease treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing collaborations between pharmaceutical companies and research institutions enhancing thyroid eye disease treatment product
    • 5.1.3.2. Rising advancements in innovation of thyroid eye disease treatment to enhance novel therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects and adverse reactions associated with current thyroid eye disease treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Increasing need for surgical treatments to restore visual function and cosmetic appearance among patients
  • 5.2.2. Route of Administration: Rising preference for intravenous administration owing to efficacy and immediate relief
  • 5.2.3. Type: Significant importance of thyroid eye disease treatments for treating type I TED for controlling inflammation and preventing progression
  • 5.2.4. Diagnosis: Increasing significance for orbital ultrasound owing to its non-invasive appeal and cost-effectiveness
  • 5.2.5. End-User: Expanding adoption of thyroid eye disease treatments across outpatient centers with rising need for convenient and cost-effective treatment solutions
  • 5.2.6. Distribution: Growing importance of hospital pharmacies owing to seamless access to specialized treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Thyroid Eye Disease Treatments Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medical Treatment
  • 6.2.1. Corticosteroids
  • 6.2.2. Immunosuppressants
  • 6.2.3. Monoclonal Antibodies
  • 6.2.4. Thyroid Hormone Control
  • 6.2.5. Tyrosine Kinase Inhibitors
• 6.3. Surgical Treatment
  • 6.3.1. Eyelid Surgery
  • 6.3.2. Orbital Decompression Surgery
  • 6.3.3. Strabismus Surgery

7. Thyroid Eye Disease Treatments Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Oral
• 7.4. Topical

8. Thyroid Eye Disease Treatments Market, by Type

• 8.1. Introduction
• 8.2. Type I TED
• 8.3. Type II TED

9. Thyroid Eye Disease Treatments Market, by Diagnosis

• 9.1. Introduction
• 9.2. Blood Test
• 9.3. Imaging Test
• 9.4. Orbital Ultrasound
• 9.5. Radioactive Iodine Uptake Test

10. Thyroid Eye Disease Treatments Market, by End-User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Outpatient Centers
• 10.4. Specialty Clinics

11. Thyroid Eye Disease Treatments Market, by Distribution

• 11.1. Introduction
• 11.2. Hospital Pharmacy
• 11.3. Online Pharmacy
• 11.4. Retail Pharmacy

12. Americas Thyroid Eye Disease Treatments Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Thyroid Eye Disease Treatments Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Sling Therapeutics reveals advance phase 2b/3 trial results for linsitinib in thyroid eye disease management
  • 15.3.2. Acelyrin, Inc. announces new Phase 2 data and Phase 3 plans for lonigutamab in treating thyroid eye disease
  • 15.3.3. Lundbeck launches advance clinical trial of CD40L blocker Lu AG22515 targeting thyroid eye disease
  • 15.3.4. Amgen announced TEPEZZA approval in Japan marks a significant advancement in thyroid eye disease treatment
  • 15.3.5. Viridian Therapeutics enhances with Phase III trials of VRDN-003 for treating thyroid eye disease
  • 15.3.6. Verana Health announces launch of Qdata thyroid eye disease
  • 15.3.7. Xeris Biopharma finalizes worldwide licensing agreement for Xeriject teprotumumab in thyroid eye disease treatment
  • 15.3.8. Viridian Therapeutics partners with Ypsomed AG to enhance subcutaneous thyroid eye disease treatment
  • 15.3.9. Amgen completes acquisition of Horizon Therapeutics to expand rare disease treatment portfolio
  • 15.3.10. Tourmaline Bio announces FDA clearance of Investigational New Drug application for TOUR006
• 15.4. Strategy Analysis & Recommendation
  • 15.4.1. Sling Therapeutics, Inc.
  • 15.4.2. Amgen Inc.
  • 15.4.3. Viridian Therapeutics, Inc. by miRagen Therapeutics, Inc.
  • 15.4.4. ACELYRIN, INC.

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. ACELYRIN, INC.
• 4. Amgen Inc.
• 5. argenx SE
• 6. Bausch & Lomb Incorporated
• 7. Biocon Limited
• 8. BioXpress Therapeutics SA
• 9. Cipla Limited
• 10. Dr. Reddy's Laboratories Ltd.
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche AG
• 13. Genmab A/S
• 14. GlaxoSmithKline PLC
• 15. H. Lundbeck A/S
• 16. Hetero Drugs Limited
• 17. Immunovant, Inc.
• 18. Intas Pharmaceuticals Ltd.
• 19. Johnson & Johnson Services Inc.
• 20. Lupin Limited
• 21. Merck KGaA
• 22. Novartis AG
• 23. Pfizer, Inc.
• 24. Regeneron Pharmaceuticals, Inc.
• 25. Sling Therapeutics, Inc.
• 26. Teva Pharmaceutical Industries Ltd.
• 27. Viridian Therapeutics, Inc.